PPARG and Hepatic fibrosis: Here, we sought to selectively activate PPARγ in liver macrophages with a low dose of the GW1929 agonist linked to dendrimer–graphene nanostars to selectively stimulate a M2 anti-inflammatory macrophage phenotype and to boost macrophage-driven liver fibrosis resolution.